Related Experiment Video
Updated: Oct 16, 2025

Visualization of Amyloid β Deposits in the Human Brain with Matrix-assisted Laser Desorption/Ionization Imaging Mass Spectrometry
Published on: March 7, 2019
Relationship between Cerebrospinal Fluid Matrix Metalloproteinases Levels and Brain Amyloid Deposition in Mild
Yuuki Sasaki1, Noriyuki Kimura1, Yasuhiro Aso1
1Department of Neurology, Faculty of Medicine, Oita University, Oita 879-5593, Japan.
Abstract:
This study aimed to explore whether cerebrospinal fluid (CSF) levels of matrix metalloproteinases (MMPs), and their inhibitors (TIMPs) were associated with brain amyloid deposition, cortical glucose metabolism, and white matter lesions (WMLs) in individuals with amnestic mild cognitive impairment (MCI). A total of 33 individuals with amnestic MCI (mean age, 75.6 years) underwent 11C-Pittsburgh compound B positron emission tomography (PiB-PET), 18F-fluorodeoxyglucose positron emission tomography, magnetic resonance imaging or computed tomography, and CSF analysis. PET uptake of the frontal and temporoparietal lobes and posterior cingulate gyrus was assessed using the cerebellar cortex as the reference region. WMLs were assessed by the Fazekas scale. CSF levels of MMPs and TIMPs were measured with bead-based multiplex assays. After adjusting for covariates, multiple linear regression analysis showed that CSF levels of MMP-2 were negatively correlated with global PiB uptake (p = 0.035), especially in the parietotemporal lobe and posterior cingulate gyrus (p = 0.016 and p = 0.041, respectively). Moreover, CSF levels of MMP-7 were positively correlated with the severity of WMLs (p = 0.033). CSF levels of MMP-2 and MMP-7 are associated with brain amyloid deposition and severity of WMLs, respectively. These findings provide valuable insights into the role of MMPs in amyloid β catabolism and blood-brain barrier integration at the MCI stage.
Insights
Cerebrospinal fluid (CSF) matrix metalloproteinases (MMPs) are linked to brain amyloid deposition and white matter lesion severity in mild cognitive impairment (MCI). Specifically, MMP-2 correlates with amyloid, while MMP-7 relates to lesion severity.
Area of Science:
- Neuroscience
- Biochemistry
- Medical Imaging
Background:
- Mild cognitive impairment (MCI) is a prodromal stage of dementia, characterized by cognitive decline.
- Matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) play roles in extracellular matrix remodeling and have been implicated in neurodegenerative diseases.
- Understanding the relationship between MMPs/TIMPs and neuropathological hallmarks in MCI is crucial for early diagnosis and intervention.
Purpose of the Study:
- To investigate the association between cerebrospinal fluid (CSF) levels of MMPs and TIMPs with brain amyloid deposition, glucose metabolism, and white matter lesions (WMLs) in amnestic MCI.
- To explore the potential role of specific MMPs in the early stages of Alzheimer's disease pathogenesis.
Main Methods:
- Study included 33 individuals with amnestic MCI.
- Utilized 11C-Pittsburgh compound B positron emission tomography (PiB-PET) for amyloid imaging.
- Employed 18F-fluorodeoxyglucose positron emission tomography for glucose metabolism assessment.
- Assessed white matter lesions (WMLs) using MRI/CT and the Fazekas scale.
- Measured CSF levels of MMPs and TIMPs via multiplex assays.
Main Results:
- CSF MMP-2 levels showed a negative correlation with global PiB uptake, particularly in the parietotemporal lobe and posterior cingulate gyrus.
- CSF MMP-7 levels were positively correlated with the severity of white matter lesions (WMLs).
- No significant associations were found for other MMPs or TIMPs with the studied biomarkers.
Conclusions:
- CSF MMP-2 levels are associated with brain amyloid deposition in individuals with amnestic MCI.
- CSF MMP-7 levels are linked to the severity of white matter lesions in this cohort.
- These findings suggest a role for MMPs in amyloid-beta catabolism and blood-brain barrier integrity during the MCI stage.
Related Concept Videos
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
Role of Neurotransmitters in Memory
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is...

